Henderson

Researchers are evaluating the effect of abelacimab compared to a placebo in patients with atrial fibrillation (AF) who are considered unsuitable for oral anticoagulation therapy. This study focuses on people at high risk for ischemic stroke or systemic embolism and aims to assess the safety and effectiveness of abelacimab in preventing these events. The study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial involving patients with AF who have specific risk factors and treatment challenges. Participants will receive either abelacimab, provided as a liquid in vials at 150 mg/mL, or a matching placebo liquid. The study design includes parallel groups with blinded treatment assignment. The trial does not describe additional treatment phases or extensions but focuses on the comparison of abelacimab and placebo over the study duration. During the study, participants will be monitored for up to 30 months to measure the time until the first occurrence of ischemic stroke or systemic embolism, as well as the time until the first occurrence of serious bleeding as defined by the Bleeding Academic Research Consortium (BARC) type 3c/5 bleeding. Safety and efficacy will be closely evaluated, with ongoing assessments to track these outcomes throughout the follow-up period.

This research aims to help breast cancer survivors living in rural areas manage their symptoms and build healthier habits like eating well, staying active, and managing weight to reduce the risk of heart disease after cancer treatment. The study focuses on women who have completed treatment for stage I-III breast cancer within the past five years and face challenges such as pain, fatigue, sadness, or distress that affect their lifestyle. It also addresses the difficulties rural survivors may have in accessing healthcare, healthy food, and exercise opportunities. Participants will be randomly assigned to either the WeCan-Rural program or receive standard health information from the National Cancer Institute. The WeCan-Rural program involves 12 weekly one-hour sessions via Zoom with a trained therapist, covering topics such as nutrition, exercise, symptom management, relaxation, and pacing strategies. Participants will receive tools like a wireless activity tracker, scale, and blood pressure monitor to help track their progress. Tablets and data plans will be provided if needed to ensure access. During the study, participants will visit their clinic twice about 12 weeks apart for weight and blood pressure checks, blood samples, and a walking test. They will also complete online surveys about their health, diet, physical activity, symptoms, and confidence in managing their health. Researchers will assess satisfaction with the program, its acceptability, and effects on weight, symptoms, diet, physical activity, heart health markers, and self-management confidence. The total study duration is about 12 to 14 weeks after baseline.